Shared on 02 Nov 25
Fair value Increased 5.74%Analysts have raised their price target for AlzChem Group from €154.24 to €163.10. They cite improved profit margin projections and continued confidence in the company's financial outlook.
Shared on 20 Aug 25
Fair value Increased 14%Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
The increase in AlzChem Group’s consensus price target is primarily driven by a higher forward P/E multiple rather than changes in revenue growth forecasts, with fair value rising from €135.24 to €143.64. What's in the News AlzChem Group AG confirmed its full-year 2025 guidance, projecting organic sales growth of approximately 5% to around EUR 580 million.
Shared on 06 Aug 25
Fair value Increased 8.71%Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
AlzChem Group's higher consensus price target reflects improved profitability and a lower forward P/E, indicating stronger earnings expectations and valuation support, with fair value raised from €124.40 to €135.24. What's in the News AlzChem Group AG confirmed full year 2025 guidance, expecting approximately 5% organic sales growth to around EUR 580 million.
Shared on 29 Jul 25
Fair value Increased 24%Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
The significant upward revision in AlzChem Group’s price target is underpinned by improved consensus forecasts for both revenue growth and net profit margin, resulting in a new fair value estimate of €124.40. What's in the News AlzChem Group AG confirmed 2025 earnings guidance, expecting sales to reach approximately EUR 580 million.
Shared on 01 May 25
Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 14%Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
AnalystConsensusTarget has decreased revenue growth from 9.2% to 7.7%.
Shared on 26 Mar 25
Fair value Increased 15%Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
AnalystConsensusTarget has increased revenue growth from 7.7% to 9.2%, increased profit margin from 11.6% to 12.8% and increased shares outstanding growth rate from -0.0% to 0.0%.
Shared on 19 Mar 25
Fair value Increased 8.24%Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 13 Mar 25
Fair value Increased 25%Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
AnalystConsensusTarget has increased future PE multiple from 11.2x to 13.9x.